Updated

Updated · PR Newswire · Aug 11

Vascular Dementia Market Seen Growing 4.5% to 2036 as 3 Million Cases Lift Demand

Updated

Updated · PR Newswire · Aug 11

Vascular Dementia Market Seen Growing 4.5% to 2036 as 3 Million Cases Lift Demand

1 articles · Updated · PR Newswire · Aug 11

DelveInsight projects the vascular dementia market to expand at a 4.5% CAGR through 2036 across the seven major markets, from a 2025 base of $1.3 billion.
About 3 million diagnosed prevalent cases were recorded in the 7MM in 2025, with aging populations, higher stroke and cardiometabolic risk, and better diagnostics expected to keep demand rising.
The United States accounted for roughly 70% of the 2025 market and about 1 million diagnosed cases, making it the dominant market in the forecast.
No drug is currently approved specifically for vascular dementia, but pipeline candidates including Apabetalone, BAC, PNA1 and Rifaximin SSD are expected to support growth; Apabetalone is forecast to peak near 14% share after a projected 2032 launch.

Sources

Center100%

Will targeting gut microbiota and inflammation finally break the historic losing streak of dementia drug development by 2032?

With no approved drugs today, could emerging AI diagnostics unlock a billion-dollar market before pipeline therapies even launch?

Can novel AI frameworks and blood biomarkers truly differentiate vascular cognitive decline from Alzheimer's before irreversible damage occurs?

1 total

Center100%